Compare UAMY & IVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UAMY | IVA |
|---|---|---|
| Founded | 1968 | 2011 |
| Country | United States | France |
| Employees | N/A | 77 |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.1B |
| IPO Year | 1997 | N/A |
| Metric | UAMY | IVA |
|---|---|---|
| Price | $10.77 | $5.64 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 10 |
| Target Price | $9.44 | ★ $16.20 |
| AVG Volume (30 Days) | ★ 9.9M | 490.5K |
| Earning Date | 05-07-2026 | 03-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $39,257,708.00 | N/A |
| Revenue This Year | $219.89 | N/A |
| Revenue Next Year | $104.28 | $751.20 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 162.80 | N/A |
| 52 Week Low | $1.94 | $2.94 |
| 52 Week High | $19.71 | $7.98 |
| Indicator | UAMY | IVA |
|---|---|---|
| Relative Strength Index (RSI) | 60.29 | 48.15 |
| Support Level | $10.68 | $5.04 |
| Resistance Level | $11.01 | $5.78 |
| Average True Range (ATR) | 0.86 | 0.37 |
| MACD | 0.24 | 0.04 |
| Stochastic Oscillator | 79.36 | 76.97 |
United States Antimony Corp is a fully integrated mining, transportation, milling, smelting, and selling company. It has two operating segments: antimony and zeolite. Its products and services include antimony; silver; gold; zeolite products; and storage, handling, & packaging services. The company's geographical segments are the United States, Canada, and Mexico, of which the vast majority of its revenue comes from the United States.
Inventiva SA is a France-based biopharmaceutical company specialized in developing drugs that impact on nuclear receptors, transcription factors and epigenetic modulation. The company is focused on developing its product candidate, lanifibranor, for the treatment of patients with non-alcoholic steatohepatitis, or NASH, a disease for which there are currently no approved therapies. The company is also involved in developing a portfolio of pre-clinical therapy programs. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France. Majority of the group's revenue is derived from its research partnerships with AbbVie and BI.